

Title (en)
Polysubstituted 1,1-pyridinyloxycyclopropanamine derivatives, process for their préparation and pharmaceutical compositions containing them

Title (de)
Polysubstituierte 1,1-pyridinyloxycyclopropanamine Derivate, Verfahren zu ihrer Herstellung und die enthaltenden pharmazeutischen Zusammensetzungen

Title (fr)
Composés 1,1-pyridinyloxycyclopropanamines polysubstitués, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent

Publication
EP 1748043 A1 20070131 (FR)

Application
EP 06291219 A 20060727

Priority
FR 0508033 A 20050728

Abstract (en)
1-Pyridinyloxyalkyl-1-aminocyclopropane derivatives (I), their enantiomers, diastereoisomers and acid or base addition salts are new. 1-Pyridinyloxyalkyl-1-aminocyclopropane derivatives of formula (I), their enantiomers, diastereoisomers and acid or base addition salts are new. n : 1-6; R 1 and R 2hydrogen, 1-6C alkyl or aryl(1-6C)alkyl; R 3 and R 4hydrogen or 1-6C alkyl but not both hydrogen; R 5 and R 6hydrogen, 1-6C alkyl, halo, hydroxy, 1-6C alkoxy, cyano, nitro, 2-6C acyl, 1-6C alkoxycarbonyl, 1-6C trihaloalkyl, 1-6C trihaloalkoxy or amino, optionally substituted by 1 or 2 1-6C alkyl; and aryl : (bi)phenyl, naphthyl, di- or tetra-hydronaphthyl, indanyl or indenyl, each optionally substituted by one or more halo, 1-6C alkyl, hydroxy, cyano, nitro, 1-6C alkoxy, 2-7C acyl, 1-6C alkoxycarbonyl, 1-6C trihalo-alkyl or -alkoxy, or amino, optionally substituted by 1 or 2 1-6C alkyl. An independent claim is included for several preparations of (I). [Image] ACTIVITY : Nootropic; Neuroprotective; Antiparkinsonian; Neuroleptic; Tranquilizer; Analgesic. The compound racemic N-2-dimethyl-1-[(3-pyridinyloxy)methyl]cyclopropanamine hydrochloride (Ia) was tested by the method of Psychopharmacology, 91 (1987) 363 in which the time taken for an adult rat to recognize a young rat when encountering 2 hours after an initial meeting was measured. The difference in recognition times was 38 s for a rat treated with 10 mg/kg (intraperitoneal) of (Ia), indicating a significant improvement in memory. MECHANISM OF ACTION : Central nicotinic alpha 4beta 2 receptors Ligand.

IPC 8 full level
C07D 213/65 (2006.01); **A61K 31/44** (2006.01); **A61P 25/16** (2006.01); **A61P 25/26** (2006.01); **A61P 25/28** (2006.01); **A61P 25/30** (2006.01)

CPC (source: EP KR US)
A61K 31/4412 (2013.01 - KR); **A61P 25/00** (2017.12 - EP); **A61P 25/04** (2017.12 - EP); **A61P 25/14** (2017.12 - EP); **A61P 25/16** (2017.12 - EP); **A61P 25/18** (2017.12 - EP); **A61P 25/24** (2017.12 - EP); **A61P 25/26** (2017.12 - EP); **A61P 25/28** (2017.12 - EP); **A61P 25/30** (2017.12 - EP); **A61P 25/34** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07D 213/65** (2013.01 - EP KR US); **C07B 2200/07** (2013.01 - KR)

Citation (search report)
[A] EP 1170281 A1 20020109 - SERVIER LAB [FR]

Cited by
CN102741239A; EA020506B1; US8735423B2; WO2011061751A1

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

Designated extension state (EPC)
AL BA HR MK YU

DOCDB simple family (publication)
EP 1748043 A1 20070131; EP 1748043 B1 20080820; AR 054875 A1 20070725; AT E405550 T1 20080915; AU 2006203241 A1 20070215; BR PI0603064 A 20070814; CA 2552827 A1 20070128; CN 100519531 C 20090729; CN 1903843 A 20070131; DE 602006002328 D1 20081002; DK 1748043 T3 20081208; EA 011126 B1 20081230; EA 200601248 A1 20070427; ES 2313589 T3 20090301; FR 2889187 A1 20070202; FR 2889187 B1 20070907; GE P20084548 B 20081125; HR P20080536 T3 20090228; HR P20080536 T5 20090331; JP 2007077135 A 20070329; KR 100824830 B1 20080423; KR 20070015011 A 20070201; MA 28426 B1 20070201; MX PA06008415 A 20070129; NO 20063461 L 20070129; NZ 548747 A 20070629; PL 1748043 T3 20081231; PT 1748043 E 20081007; SG 129411 A1 20070226; SI 1748043 T1 20081231; US 2007027191 A1 20070201; US 7348344 B2 20080325; WO 2007012762 A1 20070201; ZA 200606277 B 20070425

DOCDB simple family (application)
EP 06291219 A 20060727; AR P060103249 A 20060727; AT 06291219 T 20060727; AU 2006203241 A 20060728; BR PI0603064 A 20060728; CA 2552827 A 20060720; CN 200610108932 A 20060728; DE 602006002328 T 20060727; DK 06291219 T 20060727; EA 200601248 A 20060727; ES 06291219 T 20060727; FR 0508033 A 20050728; FR 2006001832 W 20060727; GE AP2006009543 A 20060727; HR P20080536 T 20081119; JP 2006206041 A 20060728; KR 20060070569 A 20060727; MA 29177 A 20060710; MX PA06008415 A 20060726; NO 20063461 A 20060727; NZ 54874706 A 20060726; PL 06291219 T 20060727; PT 06291219 T 20060727; SG 200604914 A 20060721; SI 200630083 T 20060727; US 49307006 A 20060726; ZA 200606277 A 20060728